Media headlines about Threshold Pharmaceuticals (NASDAQ:MTEM) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Threshold Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1398038430373 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies (businesswire.com)
- Molecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements (globenewswire.com)
- Benzinga’s Top Upgrades, Downgrades For August 3, 2017 – Benzinga (benzinga.com)
- Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next … – Business Wire (press release) (businesswire.com)
- 5.87 – MarketWatch (marketwatch.com)
Several brokerages have weighed in on MTEM. ValuEngine raised shares of Threshold Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Stifel Nicolaus reissued a “hold” rating and set a $0.40 price objective on shares of Threshold Pharmaceuticals in a report on Thursday, August 3rd. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Threshold Pharmaceuticals in a report on Thursday, August 3rd. They set a “buy” rating and a $10.00 price objective for the company.
Shares of Threshold Pharmaceuticals (MTEM) traded down 1.64% on Tuesday, reaching $6.00. 102,356 shares of the company’s stock traded hands. The company’s 50-day moving average is $5.05 and its 200-day moving average is $5.70. The firm’s market capitalization is $39.05 million. Threshold Pharmaceuticals has a 52 week low of $3.85 and a 52 week high of $16.28.
Threshold Pharmaceuticals (NASDAQ:MTEM) last posted its earnings results on Monday, July 31st. The biotechnology company reported $0.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.99. The firm had revenue of $3 million during the quarter. Equities research analysts anticipate that Threshold Pharmaceuticals will post ($1.32) earnings per share for the current fiscal year.
In other news, Director Jeffrey W. Bird bought 510,703 shares of the stock in a transaction dated Thursday, June 1st. The shares were acquired at an average price of $0.57 per share, with a total value of $291,100.71. Following the acquisition, the director now owns 919 shares in the company, valued at $523.83. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 12.97% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Threshold Pharmaceuticals (NASDAQ:MTEM) Given News Impact Rating of 0.21” was originally posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/threshold-pharmaceuticals-nasdaqmtem-given-news-impact-rating-of-0-21/1410607.html.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.